Condition: Chronic Diabetic Foot Ulcers · Sponsor: Oneness Biotech Co., Ltd.
The primary efficacy endpoint for this study is the proportion of subjects with complete closure of Target Ulcer during the 20-week Treatment Phase, which is assessed by the blinded independent evaluator.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Oneness Investigational Site | Mesa, Arizona, United States | — |
| Oneness Investigational Site | Carlsbad, California, United States | — |
| Oneness Investigational Site | Castro Valley, California, United States | — |
| Oneness Investigational Site | Fresno, California, United States | — |
| Oneness Investigational Site | San Francisco, California, United States | — |
| Oneness Investigational Site | Sylmar, California, United States | — |
| Oneness Investigational Site | Miami, Florida, United States | — |
| Oneness Investigational Site | Miami Lakes, Florida, United States | — |
| Oneness Investigational Site | North Miami Beach, Florida, United States | — |
| Oneness Investigational Site | Mount Prospect, Illinois, United States | — |
| Oneness Investigational Site | O'Fallon, Illinois, United States | — |
| Oneness Investigational Site | Springfield, Illinois, United States | — |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04962139